Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 31 to 40 of 872

TitleReference numberPublishedLast updated
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)TA1089
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollenTA1087
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTA1085
Cenobamate for treating focal onset seizures in epilepsyTA753
Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)TA1082
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)TA1083
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)TA1084
Fruquintinib for previously treated metastatic colorectal cancerTA1079
Mirikizumab for previously treated moderately to severely active Crohn's diseaseTA1080

Results per page

  1. 10
  2. 25
  3. 50
  4. All